Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40

Leerink Partners has maintained an Outperform rating on BlossomHill Therapeutics (NASDAQ: BLSM) and raised its price target from $36 to $40. This adjustment reflects increased confidence in the company's performance.